RBC Capital lowered the firm’s price target on Verve Therapeutics (VERV) to $17 from $20 and keeps an Outperform rating on the shares after its Q3 results. The first-gen PCSK9 program remains on enrollment pause due to ALT elevation/thrombocytopenia previously reported, but the next-gen designed to spare the toxicities has been dosed in 7 patients with no lab abnormalities reported to date, the analyst tells investors in a research note. The first-gen setback is unfortunate, but RBC is encouraged by clean safety so far for next- gen, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VERV:
- Verve Therapeutics price target raised to $32 from $29 at Canaccord
- Verve Therapeutics price target lowered to $14 from $15 at H.C. Wainwright
- Verve Therapeutics Reports Q3 Progress and Financials
- Verve Therapeutics reports Q3 EPS (59c), consensus (70c)
- Verve Therapeutics sees cash runway through 2026
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
